[Drugs interfering with somatostatin receptors].

Minerva Endocrinol

Facoltà di Medicina e Chirurgia, Dipartimento di Medicina Sperimentale, Sezione di Farmacologia Leonardo Donatelli, Seconda Università degli Studi, Naples, Italy.

Published: September 2001

The use of drugs interfering with somatostatin receptors (ssR) is now consolidated practice in diagnostics and therapy, stimulating the development of new and more efficient molecules offering improved pharmacodynamics. Over the years, we have passed from the use of native somatostatin to mini-somatostatin and then octapeptides, above all octreotide. Subsequently, peptides were synthesized with specific affinities for a single receptorial subtype, like compound BIM23268 and compound CH275. More recently, somatostatin analogs were synthesized with a non-peptide structure. Another important aspect in the history of sst analogs is represented by the development of new pharmaceutical formulas for these drugs in order to improve patient compliance by reducing dose frequency.

Download full-text PDF

Source

Publication Analysis

Top Keywords

interfering somatostatin
8
[drugs interfering
4
somatostatin
4
somatostatin receptors]
4
receptors] drugs
4
drugs interfering
4
somatostatin receptors
4
receptors ssr
4
ssr consolidated
4
consolidated practice
4

Similar Publications

Background: Sunitinib, a multitarget tyrosine kinase inhibitor, showed encouraging antitumor activity and manageable toxicity in patients with advanced midgut neuroendocrine tumors (NETs) in earlier results from phase I and II trials.

Patients And Methods: In this phase II trial, patients with a nonresectable grade 1 or 2 midgut progressive NET and Eastern Cooperative Oncology Group performance status 0-1 were randomly assigned 1:1 to receive 37.5 mg sunitinib or a placebo, combined with 120 mg lanreotide autogel every 28 days.

View Article and Find Full Text PDF

Divergent input patterns to the central lateral amygdala play a duet in fear memory formation.

iScience

October 2024

NMPA Key Laboratory for Research and Evaluation of Narcotic and Psychotropic Drugs, Xuzhou 221002, Jiangsu, China.

Somatostatin (SOM)-expressing neurons in the central lateral amygdala (CeL) are responsible for fear memory learning, but the circuit and molecular mechanisms underlying this biology remain elusive. Here, we found that glutamatergic neurons in the lateral parabrachial nucleus (LPB) directly dominated the activity of CeL neurons, and that selectively inhibiting the LPB→CeL pathway suppressed fear memory acquisition. By contrast, inhibiting CeL-projecting glutamatergic neurons in the paraventricular thalamic nucleus (PVT) interfered with consolidation-related processes.

View Article and Find Full Text PDF

Input specificity of NMDA-dependent GABAergic plasticity in the hippocampus.

Sci Rep

September 2024

Department of Biophysics and Neuroscience, Wroclaw Medical University, 3a Chalubinskiego Str., 50-368, Wroclaw, Poland.

Article Synopsis
  • Sensory experiences lead to lasting changes in synapses, crucial for memory, but the interaction between excitatory and inhibitory synaptic changes is not fully understood.
  • This study examined how NMDA-induced plasticity affects both excitatory and inhibitory synapses in hippocampal CA1 pyramidal cells using several experimental techniques.
  • Results revealed distinct patterns of long-term changes in inhibitory inputs, suggesting a complex relationship between excitation and inhibition, which could help maintain the balance in brain activity and influence how neurons process information.
View Article and Find Full Text PDF

Knockdown of Lhx6 during embryonic development results in neurophysiological alterations and behavioral deficits analogous to schizophrenia in adult rats.

Schizophr Res

May 2024

Department of Pharmacology and Center for Biomedical Neuroscience, University of Texas Health Science Center, San Antonio, TX 78229, USA; South Texas Veterans Health Care System, Audie L. Murphy Division, San Antonio, USA.

A decreased expression of specific interneuron subtypes, containing either the calcium binding protein parvalbumin (PV) or the neurotransmitter somatostatin (SST), are observed in the cortex and hippocampus of both patients with schizophrenia and rodent models used to study the disorder. Moreover, preclinical studies suggest that this loss of inhibitory function is a key pathological mechanism underlying the symptoms of schizophrenia. Interestingly, decreased expression of Lhx6, a key transcriptional regulator specific to the development and migration of PV and SST interneurons, is seen in human postmortem studies and following multiple developmental disruptions used to model schizophrenia preclinically.

View Article and Find Full Text PDF

Transient expression of somatostatin (SST) has been observed in the olfactory epithelium (OE) and nerves of chick embryos. Intense expression of SST in these regions on embryonic days (E) 5-8 coincides with the migration of neurons producing gonadotropin-releasing hormone (GnRH) from the OE to the forebrain (FB), suggesting that SST plays a role in the development of GnRH neurons. Using in ovo electroporation of small interfering RNA, we found that the suppression of SST mRNA in the olfactory placode (OP) of E3.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!